•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A02715 Summary:

BILL NOA02715
 
SAME ASNo Same As
 
SPONSORReyes
 
COSPNSRTapia, Cruz, Alvarez, Zaccaro, Shimsky, Steck, Raga, Lunsford, Levenberg, Meeks
 
MLTSPNSR
 
Amd §365-a, Soc Serv L
 
Requires Medicaid to provide comprehensive coverage for the treatment of obesity including coverage for intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medication.
Go to top

A02715 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          2715
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                    January 22, 2025
                                       ___________
 
        Introduced  by M. of A. REYES -- read once and referred to the Committee
          on Health
 
        AN ACT to amend the social services law, in relation to expanding  Medi-
          caid  coverage  to include comprehensive coverage for the treatment of
          obesity
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.  Subdivision 2 of section 365-a of the social services law
     2  is amended by adding a new paragraph (nn) to read as follows:
     3    (nn) (i) comprehensive coverage for treatment  of  obesity,  including
     4  coverage  for  intensive  behavioral  therapy,  bariatric  surgery,  and
     5  FDA-approved anti-obesity medication, when such services are provided by
     6  a health care practitioner  licensed,  certified,  or  authorized  under
     7  title  eight  of  the  education  law, acting within such practitioner's
     8  lawful scope of practice.
     9    (ii)  coverage  criteria  for  FDA-approved  anti-obesity  medications
    10  pursuant  to  subparagraph  (i)  of  this  paragraph  shall  not be more
    11  restrictive than the FDA-approved indications for such treatments.
    12    (iii) coverage provided pursuant to this paragraph  shall  be  neither
    13  different  nor  separate from coverage for any other illness, condition,
    14  or disorder for purposes of  determining  deductibles,  lifetime  dollar
    15  limits,  copayment and coinsurance factors, and benefit year maximum for
    16  deductibles and copayment and coinsurance factors.
    17    (iv) nothing in this  paragraph  shall  preclude  the  undertaking  of
    18  utilization  management to determine the medical necessity for treatment
    19  of obesity under this section, provided that  all  such  appropriateness
    20  and medical necessity determinations are made in the same manner as such
    21  determinations  are  made for the treatment of any other illness, condi-
    22  tion, or disorder covered by this section.
    23    (v) the Medicaid program shall provide notice to its enrollees regard-
    24  ing the coverage required by this section. The notice shall be in  writ-
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD03144-01-5

        A. 2715                             2
 
     1  ing  and prominently positioned in any literature or correspondence sent
     2  to enrollees and shall be transmitted to enrollees when annual  informa-
     3  tion  is  made available to enrollees, or in any other mailing to enrol-
     4  lees, provided that such notice is provided to enrollees enrolled on the
     5  effective  date  of  this  paragraph  no  later than one year after such
     6  effective date.
     7    (vi) for the purposes of this paragraph,  the  following  terms  shall
     8  have the following meanings:
     9    (1)  "Comprehensive  coverage  for treatment of obesity" shall include
    10  coverage  for  intensive  behavioral  therapy,  bariatric  surgery,  and
    11  FDA-approved anti-obesity medication.
    12    (2)  "FDA-approved  anti-obesity medication" shall mean any medication
    13  approved by the federal food and drug administration with an  indication
    14  for chronic weight management in patients with obesity.
    15    § 2. This act shall take effect on the one hundred eightieth day after
    16  it  shall have become a law. Effective immediately, the addition, amend-
    17  ment and/or repeal of any rule or regulation necessary for the implemen-
    18  tation of this act on its effective date are authorized to be  made  and
    19  completed on or before such effective date.
Go to top